STATE STREET CORP - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 100 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$4,038,984
-20.1%
741,098
-0.5%
0.00%
Q2 2023$5,055,882
+32.3%
744,607
-2.4%
0.00%
Q1 2023$3,821,778
-52.9%
762,830
-54.2%
0.00%
Q4 2022$8,121,794
-70.7%
1,664,302
-13.3%
0.00%
-100.0%
Q3 2022$27,674,000
+4.9%
1,919,139
+10.1%
0.00%0.0%
Q2 2022$26,374,000
-3.8%
1,743,142
-24.5%
0.00%
+100.0%
Q1 2022$27,428,000
+16.2%
2,308,782
+58.5%
0.00%0.0%
Q4 2021$23,613,000
-37.9%
1,456,670
+9.4%
0.00%
-50.0%
Q3 2021$38,014,000
-19.1%
1,331,943
-4.1%
0.00%0.0%
Q2 2021$46,965,000
-9.1%
1,389,511
-18.7%
0.00%
-33.3%
Q1 2021$51,693,000
+10.7%
1,709,421
+81.3%
0.00%0.0%
Q4 2020$46,688,000
+15.8%
943,003
-10.2%
0.00%0.0%
Q3 2020$40,307,000
-2.4%
1,049,936
+9.9%
0.00%0.0%
Q2 2020$41,281,000
+100.6%
955,589
+21.2%
0.00%
+50.0%
Q1 2020$20,577,000
-12.0%
788,395
+5.4%
0.00%0.0%
Q4 2019$23,379,000
+153.5%
748,116
+111.4%
0.00%
+100.0%
Q3 2019$9,224,000
+25.2%
353,935
+9.9%
0.00%0.0%
Q2 2019$7,365,000
+242.1%
322,057
+292.0%
0.00%
Q1 2019$2,153,000
+61.9%
82,162
+25.6%
0.00%
Q4 2018$1,330,00065,3970.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 216,916$6,191,0003.86%
Sofinnova Investments, Inc. 2,194,278$62,625,0003.71%
MPM BioImpact LLC 452,970$12,928,0002.00%
Soleus Capital Management, L.P. 265,700$7,583,0001.18%
ASHFORD CAPITAL MANAGEMENT INC 452,110$12,903,0001.17%
ORACLE INVESTMENT MANAGEMENT INC 315,642$9,008,0001.12%
First Light Asset Management, LLC 577,663$16,487,0001.09%
Lombard Odier Asset Management (Switzerland) SA 352,839$10,070,0000.62%
Cormorant Asset Management, LP 500,000$14,270,0000.58%
Artal Group S.A. 400,000$11,416,0000.26%
View complete list of Y-MABS THERAPEUTICS INC shareholders